Serum creatinine and cystatin C-based index can be a screening biomarker for sarcopenia in older population
Key summary points
To use an index based on blood biomarkers (serum creatinine and cystatin c) to screen sarcopenia in older adults.
Lower value of Biochemical Total Body Muscle mass index (TBMM) (calculated from serum creatinine and cystatin C) was significantly associated with higher risk of sarcopenia.
Biochemical Total Body Muscle Mass index based on serum creatinine and cystatin C can be used to screen sarcopenia in older people.
Considering the clinical impact of sarcopenia, it would be interesting to get a rapid and sensible screening tool. We conducted a cross-sectional study with the motive to use an index based on serum creatinine and cystatin C to screen sarcopenia in older people in outpatient settings.
100 participants above the age of 65 years were recruited from the outpatient department of Geriatric medicine of a tertiary care hospital in India. Muscle mass, muscle strength and physical performance were measured by DXA scan, hand-held dynamometer and 4 m gait speed, respectively. Sarcopenia was identified using Asian working group of sarcopenia (AWGS) criteria. Serum creatinine and cystatin C were measured for all participants. Serum creatinine/cystatin C ratio and biochemical total body muscle mass index (TBMM) were calculated and its association was checked with sarcopenia.
The prevalence of sarcopenia was 53%. Mean serum creatinine/cystatin C ratio was 74.79 ± 24.91. It was not significantly associated with sarcopenia. Mean biochemical TBMM index of participants was 36.40 ± 7.88 (males—38.77 ± 7.72, females—31.22 ± 5.13). The lower value of biochemical TBMM index was significantly associated with an increased risk of sarcopenia (p < 0.01). Cut-off value of 40.9 in males (sensitivity—79.41%; specificity—61.76%) and 32.2 in females (sensitivity—78.95%; specificity—66.67%) was proposed for identification of sarcopenia.
Out of the two indices, only low biochemical total body muscle mass index is significantly associated with sarcopenia and a value of less than 40.9 in males and 32.2 in females can be used to screen sarcopenia in older people.
KeywordsSarcopenia Biomarkers Creatinine Cystatin C
This work was supported by National Programme for Health Care of the Elderly, Government of India.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (IECPG-111/12/2015) and with the 1964 Helsinki Declaration and its later amendments.
Informed consent was obtained from all individual participants included in the study.